Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
24 03 2020
Historique:
received: 18 09 2019
accepted: 28 01 2020
pubmed: 6 2 2020
medline: 12 1 2021
entrez: 5 2 2020
Statut: epublish

Résumé

Herein, we phenotypically and enzymatically characterize the theoretical mutation Q579I in helix K and the already described clinical mutation K805Q in helix P of cytomegalovirus DNA polymerase for susceptibility to foscarnet. Q579I and K805Q recombinant viruses were hypersusceptible to foscarnet (respective mean 50% effective concentrations [EC

Identifiants

pubmed: 32015044
pii: AAC.01910-19
doi: 10.1128/AAC.01910-19
pmc: PMC7179328
pii:
doi:

Substances chimiques

Antiviral Agents 0
DNA, Viral 0
Foscarnet 364P9RVW4X
DNA-Directed DNA Polymerase EC 2.7.7.7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : CIHR
ID : 148361
Pays : Canada

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

J Virol. 2006 Feb;80(3):1440-50
pubmed: 16415021
Nat Struct Mol Biol. 2009 Sep;16(9):979-86
pubmed: 19718023
J Biol Chem. 2011 Jul 15;286(28):25246-55
pubmed: 21566148
Virus Res. 2017 Apr 15;234:177-192
pubmed: 28153606
Antimicrob Agents Chemother. 2011 Sep;55(9):4019-27
pubmed: 21709106
Antivir Ther. 2010;15(4):579-86
pubmed: 20587851
J Biol Chem. 2006 Jun 30;281(26):18193-200
pubmed: 16638752
J Clin Microbiol. 2013 Oct;51(10):3216-24
pubmed: 23863570
Infect Disord Drug Targets. 2009 Apr;9(2):201-22
pubmed: 19275707
J Infect Dis. 2014 Apr 15;209(8):1219-26
pubmed: 24273181
Clin Microbiol Infect. 2007 Oct;13(10):953-63
pubmed: 17803749
Protein Expr Purif. 1997 Nov;11(2):209-18
pubmed: 9367818
Clin Microbiol Rev. 2010 Oct;23(4):689-712
pubmed: 20930070
J Infect Dis. 2019 Sep 13;220(8):1302-1306
pubmed: 31199457
J Clin Virol. 2011 Apr;50(4):287-91
pubmed: 21295516
J Virol. 1998 Jul;72(7):5927-36
pubmed: 9621055
Viruses. 2013 Jan 08;5(1):54-86
pubmed: 23299784
J Virol. 2015 Apr;89(8):4636-44
pubmed: 25673718

Auteurs

Karima Zarrouk (K)

Research Center in Infectious Diseases, CHU de Québec-Laval University, Quebec City, Quebec, Canada.

Van Dung Pham (VD)

Department of Biochemistry, Microbiology, and Bioinformatics, PROTEO, Laval University, Quebec City, Quebec, Canada.
Institute of Integrative and Systems Biology, Laval University, Quebec City, Quebec, Canada.

Jocelyne Piret (J)

Research Center in Infectious Diseases, CHU de Québec-Laval University, Quebec City, Quebec, Canada.

Rong Shi (R)

Department of Biochemistry, Microbiology, and Bioinformatics, PROTEO, Laval University, Quebec City, Quebec, Canada.
Institute of Integrative and Systems Biology, Laval University, Quebec City, Quebec, Canada.

Guy Boivin (G)

Research Center in Infectious Diseases, CHU de Québec-Laval University, Quebec City, Quebec, Canada Guy.Boivin@crchudequebec.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH